Name | Type | Posted | Actions |
|---|---|---|---|
Notice of Intent to Sole Source.pdf | May 19, 2026 |
Modification to the A11 HERV-E TCR and T cell product to improve the therapeutic efficacy for ccRCC patients.
Contact and place of performance
FALZONE, MICHAEL L
Bethesda, MD 20892
USA
Attachment: Notice of Intent to Sole Source
The National Institutes of Health (NIH), Office of Logistics and Acquisition Operations (OLAO), issued this pre-solicitation notice, solicitation number 75N98026Q00392, regarding modifications to the A11 HERV-E TCR and T cell product. The primary objective is to enhance the therapeutic efficacy of these products for patients with clear cell renal cell carcinoma (ccRCC). This requirement is classified under NAICS code 622110, General Medical and Surgical Hospitals, and PSC R499, Support- Professional: Other. There is no set-aside designated for this procurement.
The performance of these services will take place in Bethesda, Maryland. The agency intends to move forward with a sole-source award, as documented in the attached Notice of Intent to Sole Source. Interested parties must submit responses by the deadline of June 3, 2026. Michael L. Falzone serves as the primary point of contact for this requirement.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.